WO2002000164A8 - Chemosensitizer - Google Patents

Chemosensitizer

Info

Publication number
WO2002000164A8
WO2002000164A8 PCT/IB2001/001133 IB0101133W WO0200164A8 WO 2002000164 A8 WO2002000164 A8 WO 2002000164A8 IB 0101133 W IB0101133 W IB 0101133W WO 0200164 A8 WO0200164 A8 WO 0200164A8
Authority
WO
WIPO (PCT)
Prior art keywords
chemotherapeutic agents
found
group
agents
chemosensitizer
Prior art date
Application number
PCT/IB2001/001133
Other languages
French (fr)
Other versions
WO2002000164A2 (en
WO2002000164A3 (en
Original Assignee
Khamar Bakulesh Mafatlal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Khamar Bakulesh Mafatlal filed Critical Khamar Bakulesh Mafatlal
Priority to EP01940915A priority Critical patent/EP1296682A4/en
Priority to EA200200288A priority patent/EA005672B1/en
Priority to APAP/P/2002/002453A priority patent/AP2002002453A0/en
Priority to AU74403/01A priority patent/AU7440301A/en
Publication of WO2002000164A2 publication Critical patent/WO2002000164A2/en
Publication of WO2002000164A8 publication Critical patent/WO2002000164A8/en
Publication of WO2002000164A3 publication Critical patent/WO2002000164A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Chemotherapeutic agents are used to treat infections caused by bacteria, virus, protozoa, parasites, and various malignant diseases like cancer. The major problem associated with use of chemotherapeutic agents is resistance to chemoptherapeutic agents. The drugs restoring sensitivity of chemotherapeutic agents are broadly known as chemosensitizers. Compounds belonging to a group of R-1-3-benzodiaxole are found to be chemosensitizer as per the present invention. Piperine is one such compound belonging to R-1-2benzodiaxole group. It is found to reverse resistance to chemotherapeutic agents like rifampicin at a dose which is easily achievable after oral ingestion of the drug.
PCT/IB2001/001133 2000-06-26 2001-06-26 Chemosensitizer WO2002000164A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP01940915A EP1296682A4 (en) 2000-06-28 2001-06-26 Chemosensitizer
EA200200288A EA005672B1 (en) 2000-06-28 2001-06-26 Chemosensitizer
APAP/P/2002/002453A AP2002002453A0 (en) 2000-06-28 2001-06-26 Chemosensitizer
AU74403/01A AU7440301A (en) 2000-06-26 2001-06-26 Chemosensitizer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN591/MUM/2000 2000-06-26
IN591MU2000 2000-06-28

Publications (3)

Publication Number Publication Date
WO2002000164A2 WO2002000164A2 (en) 2002-01-03
WO2002000164A8 true WO2002000164A8 (en) 2002-05-16
WO2002000164A3 WO2002000164A3 (en) 2002-10-24

Family

ID=11097259

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2001/001133 WO2002000164A2 (en) 2000-06-26 2001-06-26 Chemosensitizer

Country Status (6)

Country Link
EP (1) EP1296682A4 (en)
AP (1) AP2002002453A0 (en)
AU (1) AU7440301A (en)
EA (1) EA005672B1 (en)
RU (1) RU2002107449A (en)
WO (1) WO2002000164A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003223111A1 (en) * 2003-03-31 2004-10-25 Council Of Scientific And Industrial Research Use of cuminum cyminum extract and piperine for potentiation of bioefficacy of anti infectives
US8580752B2 (en) * 2005-03-31 2013-11-12 Council Of Scientitic And Industrial Research Aromatic amides as potentiators of bioefficacy of anti-infective drugs
CA2653756A1 (en) 2006-06-26 2008-01-03 The University Of British Columbia Secreted protein acidic and rich in cysteine (sparc) as chemotherapeutic sensitizers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN176897B (en) * 1993-10-29 1996-09-28 Cadila Lab Ltd
EP0650728B1 (en) * 1993-10-29 2002-02-27 Council of Scientific and Industrial Research Pharmaceutical compositions containing piperine and an antituberculosis or antileprosydrug
US5744161A (en) * 1995-02-24 1998-04-28 Sabinsa Corporation Use of piperine as a bioavailability enhancer
EP0935964A1 (en) * 1998-02-12 1999-08-18 Panacea Biotec Limited Pharmaceutical compositions containing NSAIDs and piperine

Also Published As

Publication number Publication date
EP1296682A2 (en) 2003-04-02
EA005672B1 (en) 2005-04-28
WO2002000164A2 (en) 2002-01-03
AP2002002453A0 (en) 2002-06-30
EA200200288A1 (en) 2003-02-27
RU2002107449A (en) 2003-11-20
WO2002000164A3 (en) 2002-10-24
EP1296682A4 (en) 2004-11-10
AU7440301A (en) 2002-01-08

Similar Documents

Publication Publication Date Title
EA200401019A1 (en) DOSED MEDICAL FORM FOR ORAL APPLICATION CONTAINING PDE 4 INHIBITOR AS AN ACTIVE SUBSTANCE AND POLYVINYLPYRROLIDONE AS AN AUXILIARY
NO324227B1 (en) Cyclopropyl-fused pyrrolidine-based compounds, pharmaceutical compositions and combinations containing them as well as the use thereof for the manufacture of medicaments for the treatment of diseases
FR11C0017I1 (en)
CY1109364T1 (en) A COMBINATION CONTAINING COMBRETASTATIN AND ANTI-CANCER FACTORS
MXPA03006476A (en) Pharmaceutical dosage forms of epothilones for oral administration.
TNSN06439A1 (en) DERIVATIVES OF 2-CARBAMIDE -4-PHENYLTHIAZOLE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
EE200200207A (en) Use of quinoline derivatives in the preparation of an anticancer drug, preparation of the compounds and pharmaceutical compositions containing them
IL170120A (en) 1,2,4-triazine compounds, their use for preparation of medicaments for treating or preventing hiv, pharmaceutical compositions comprising the same and processes for their preparation
ATE339406T1 (en) CHINAZOLINE COMPOUNDS AS REMEDIES
EA201101119A1 (en) DOSABLE FORM CONTAINING PANTOPRAZOL AS AN ACTIVE INGREDIENT
IT1318514B1 (en) FORMULATIONS CONTAINING A GLUCOCORTICOSTEROID DRUG FOR THE TREATMENT OF BRONCOPOLMONARY DISEASES.
WO2004073615A3 (en) Deazaflavin compounds and methods of use thereof
AU2002365439A1 (en) Preparation of pharmaceutical salts of 4 ( (z) - (4-bromophenyl) (ethoxyimino) methyl )-1'-( (2,4-dimethyl-1-oxido-3-pyridinyl) carbonyl) -4'-methyl-1,4' bipiperidine as ccr5-antagonists for the treatment of aids and related hiv infections
WO2004064757A3 (en) Absorption enhancing agents
WO2002000164A3 (en) Chemosensitizer
WO2004098577A3 (en) Dosage form containing (s)-pantoprazole as active ingredient
CY1106964T1 (en) DRUGS CONTAINING N,N'-DIPERAZINE COMPOUNDS AND THEIR USE
PT1406859E (en) Substituted 4-aminocyclohexanol derivatives
EP1273301A3 (en) Pharmaceutical preparations based on active ingredients susceptible to illict administration
EA200601015A1 (en) ORAL COMPOSITIONS OF DEOXYPEGANINE AND THEIR APPLICATION
TNSN00211A1 (en) NOVEL HYGROMYCIN DERIVATIVES, COMPOSITIONS CONTAINING THEM AND THEIR USE
MXPA05009808A (en) Treatment of proliferative diseases with epothilone derivatives and radiation.
WO2003039457A3 (en) Anti-mycobacterial compounds
ITUD20030196A1 (en) PROCEDURE FOR THE PREPARATION OF PHARMACEUTICAL DOSAGES CONTAINING MANY ACTIVE PRINCIPLES.
WO2005051489A3 (en) Fast dissolving solid oral dosage forms of galanthamine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AU BA BB BG BR BZ CA CN CO CR CU CZ DM DZ EC EE GD GE HR HU ID IL IS JP KP KR LC LK LR LT LV MA MG MN MX NO NZ PL RO SG SK TT UA US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2001IB 200101133

Country of ref document: KE

Kind code of ref document: A

Ref document number: 2001IB 200101136

Country of ref document: KE

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2001IB200101136

Country of ref document: KE

Ref document number: 2001IB200101133

Country of ref document: KE

Ref document number: 200200288

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2002 2002107449

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: AP/P/2002/002453

Country of ref document: AP

AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AU BA BB BG BR BZ CA CN CO CR CU CZ DM DZ EC EE GD GE HR HU ID IL IS JP KP KR LC LK LR LT LV MA MG MN MX NO NZ PL RO SG SK TT UA US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AU BA BB BG BR BZ CA CN CO CR CU CZ DM DZ EC EE GD GE HR HU ID IL IS JP KP KR LC LK LR LT LV MA MG MN MX NO NZ PL RO SG SK TT UA US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001940915

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001940915

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2001940915

Country of ref document: EP